(Q46642515)

English

Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design

scientific article published in July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Mauricio G. Cohen

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

author name string

T J Povsic

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

M Y Chan

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

S L Zelenkofske

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

W A Wargin

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

R A Harrington

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

J H Alexander

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

C P Rusconi

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

R C Becker

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

publication date

1 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

Journal of Thrombosis and Thrombolysis

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

32

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

21-31

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

https://scigraph.springernature.com/pub.10.1007/s11239-011-0588-3

0 references

First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0588-3

21 January 2018

Factor IXa inhibitors as novel anticoagulants

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0588-3

21 January 2018

RNA aptamers as reversible antagonists of coagulation factor IXa.

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0588-3

21 January 2018

Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0588-3

21 January 2018

A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0588-3

21 January 2018

First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0588-3

21 January 2018

A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/21503856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR

1 reference

https://pubmed.ncbi.nlm.nih.gov/21503856

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11239-011-0588-3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/21503856

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46642515&oldid=2144448294"